UNFI

United Natural Foods Inc Consumer Staples Wholesale-Groceries, General Line Russell 3000
$45.87Close $2.8BMarket cap $31.42 – $55.5252-week range Dec 1, 2026Next report

Highlights

Cautions

  • Not in an uptrend 5 of 8 trend conditions

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Aug 1, 2026 · filed Oct 22, 2026
Off 12-month high 17%
1wk down 2.2% price change
1mo up 2.4% price change
12-month return up 20% market up 11% · its own up 9%
F-score 7 / 9 Strong
Altman Z″ 1.66 Moderate risk
P/E 32.9× price / earnings
PEG — P/E / EPS growth
P/B 1.7× price / book
Earnings yield up 4.9% EBIT / enterprise value
Cheaper than 79% of the market · cheap
Revenue growth down 2% year on year
EPS growth — latest quarter
Sales growth down 1% latest quarter · +3 pts
ROE up 5% return on equity
Free cash margin up 1% $323.0M FCF
D/E 0.96 long-term debt / equity
Net debt / EBITDA 3.0×
Interest cover —EBIT / interest
Piotroski tests
  • short-term liquidity weakened
  • assets working less efficiently
  • profitable on its assets
  • generating cash from operations
  • profitability improving
  • profits backed by cash
  • reduced long-term debt
  • no new shares issued
  • gross margin widened

Repair signals

  • Long-term debt down 16% ($1.9B → $1.6B)

Trade setup

ATR% 3.4% $1.56 a day · 2×ATR $42.75
RS 54 / 99 vs the universe
Trend 5 / 8 under the 150/200-day, 50-day under the 150/200-day, RS under 70
Relative volume 1.1× vs 50-day average
Up/down volume 0.83 50 sessions
Implied move — no option chain · report Dec 1, 2026
Trend template · 5 of 8
  • Price above the 150 and 200-day averages: fails
  • 150-day average above the 200-day: passes
  • 200-day average rising for a month: passes
  • 50-day average above the 150 and 200-day: fails
  • Price above the 50-day average: passes
  • At least 30% above the 52-week low: passes
  • Within 25% of the 52-week high: passes
  • RS rank 70 or higher: fails

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Revenue shrinking Revenue fell 2.0% over the year, from $31.8B to $31.2B.
Last reported Sep 8, 2026
Results reaction Sep 8, 2026+3% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $31.2B -2% on FY2025
$0 $50B FY21 FY22 FY23 FY24 FY25 FY26 FY2021 · $26.9B FY2022 · $28.9B FY2023 · $30.3B FY2024 · $31.0B FY2025 · $31.8B FY2026 · $31.2B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $84.0M back to a profit
-$200M $0 $250M FY21 FY22 FY23 FY24 FY25 FY26 FY2021 · $149.0M FY2022 · $248.0M FY2023 · $24.0M FY2024 · -$112.0M FY2025 · -$118.0M FY2026 · $84.0M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $323.0M +35% on FY2025
-$100M $0 $500M FY21 FY22 FY23 FY24 FY25 FY26 FY2021 · $304.0M FY2022 · $80.0M FY2023 · $301.0M FY2024 · -$92.0M FY2025 · $239.0M FY2026 · $323.0M
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 13%
  • Net 0%
  • Free cash 1%
0% 20% FY21 FY22 FY23 FY24 FY25 FY26 FY2021 · Gross 15% · Net 1% · Free cash 1% FY2022 · Gross 14% · Net 1% · Free cash 0% FY2023 · Gross 14% · Net 0% · Free cash 1% FY2024 · Gross 14% · Net -0% · Free cash -0% FY2025 · Gross 13% · Net -0% · Free cash 1% FY2026 · Gross 13% · Net 0% · Free cash 1%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $1.5B net debt
  • Cash
  • Long-term debt
$0 $2.5B FY21 FY22 FY23 FY24 FY25 FY26 FY2021 · Cash $41.0M · Long-term debt $2.2B FY2022 · Cash $44.0M · Long-term debt $2.1B FY2023 · Cash $37.0M · Long-term debt $2.0B FY2024 · Cash $40.0M · Long-term debt $2.1B FY2025 · Cash $44.0M · Long-term debt $1.9B FY2026 · Cash $37.0M · Long-term debt $1.6B
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 60.30m +6.9% since FY2021
60.60m 56.40m FY21 FY22 FY23 FY24 FY25 FY26 FY2021 · 56.40m FY2022 · 58.30m FY2023 · 58.50m FY2024 · 59.50m FY2025 · 60.60m FY2026 · 60.30m
  FY2021Jul 31, 2021 FY2022Jul 30, 2022 FY2023Jul 29, 2023 FY2024Aug 3, 2024 FY2025Aug 2, 2025 FY2026Aug 1, 2026
Revenue $26.9B $28.9B $30.3B $31.0B $31.8B $31.2B
Gross margin 15% 14% 14% 14% 13% 13%
Operating income $294.0M $423.0M $120.0M $8.0M -$31.0M $211.0M
Net income $149.0M $248.0M $24.0M -$112.0M -$118.0M $84.0M
Net margin 1% 1% 0% -0% -0% 0%
Earnings per share $2.48 $4.07 $0.40 -$1.89 -$1.96 $1.34
Free cash flow $304.0M $80.0M $301.0M -$92.0M $239.0M $323.0M
Free cash margin 1% 0% 1% -0% 1% 1%
Cash $41.0M $44.0M $37.0M $40.0M $44.0M $37.0M
Long-term debt $2.2B $2.1B $2.0B $2.1B $1.9B $1.6B
Shareholders' equity $1.5B $1.8B $1.7B $1.6B $1.6B $1.6B
Shares outstanding 56.40m 58.30m 58.50m 59.50m 60.60m 60.30m

Filings

SEC EDGAR
FiledReportPeriod to Lag
Sep 14, 2026 Annual ↗ Aug 1, 2026 44d
Jun 9, 2026 Quarterly ↗ May 2, 2026 38d
Mar 10, 2026 Quarterly ↗ Jan 31, 2026 38d
Dec 2, 2025 Quarterly ↗ Nov 1, 2025 31d
Oct 1, 2025 Annual ↗ Aug 2, 2025 60d
Jun 10, 2025 Quarterly ↗ May 3, 2025 38d
Mar 11, 2025 Quarterly ↗ Feb 1, 2025 38d
Dec 10, 2024 Quarterly ↗ Nov 2, 2024 38d
Oct 1, 2024 Annual ↗ Aug 3, 2024 59d
Jun 5, 2024 Quarterly ↗ Apr 27, 2024 39d
Mar 6, 2024 Quarterly ↗ Jan 27, 2024 39d
Dec 6, 2023 Quarterly ↗ Oct 28, 2023 39d

Current reports